Which Abbott Is the One to Own Post-Split? Investorplace.com But AbbVie has a very robust pipeline, including Daclizumab (with Phase III results due in 2014), chronic kidney disease drug bardoxolone (in Phase III) and elotuzumab for multiple myeloma (in Phase III). Another dozen or so compelling Phase II drugs ... |
